Medicus Pharma Ltd.
NCM: MDCXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Medicus Pharma Ltd.'s price action across multiple timeframes using regression channels and statistical scoring.
Get MDCX Z-Score →About Medicus Pharma Ltd.
Healthcare
Drug Manufacturers - General
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. Medicus Pharma Ltd. has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in Conshohocken, Pennsylvania.
📊 Fundamental Analysis
Medicus Pharma Ltd. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -2981.2%, which indicates that capital utilization is currently under pressure.
At a current price of $0.41, MDCX currently trades near the bottom of its 52-week range (1%), indicating potential value or weakness (Range: $0.37 - $8.94).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$16.30M
Trailing P/E
--
Forward P/E
-1.02
Beta (5Y)
-0.04
52W High
$8.94
52W Low
$0.37
Avg Volume
4.03M
Day High
Day Low